ReviewJournal of asthma and allergy2018
Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history.
Review in Journal of asthma and allergy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.American journal of respiratory and critical care medicine · 2023Trial
- Article
- Japanese Patients with Severe Asthma Identified as Responders to Omalizumab Treatment at 2 Years Based on the GETE Score Continued Treatment for an Extended Period.Journal of asthma and allergy · 2024Article
- Unanswered questions on the use of biologics in pediatric asthma.The World Allergy Organization journal · 2023Review
- Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype.International journal of molecular sciences · 2023Observational
- Severe pediatric asthma with a poor response to omalizumab: a report of three cases and three-dimensional bronchial wall analysis.The Journal of international medical research · 2022Article
- A pragmatic guide to choosing biologic therapies in severe asthma.Breathe (Sheffield, England) · 2021Review
- Biological therapy for severe asthma.Asthma research and practice · 2021Review
- Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab.Biomedicines · 2021Review
- Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes.Journal of asthma and allergy · 2021Article
- FENOMA Study: Achieving Full Control in Patients with Severe Allergic Asthma.Journal of asthma and allergy · 2020Article
- Magnolol exerts anti-asthmatic effects by regulating Janus kinase-signal transduction and activation of transcription and Notch signaling pathways and modulating Th1/Th2/Th17 cytokines in ovalbumin-sensitized asthmatic mice.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2019Article
- Mast Cells and Their Progenitors in Allergic Asthma.Frontiers in immunology · 2019Review
- Article
- Two decades with omalizumab: what we still have to learn.Biologics : targets & therapy · 2018Review
- Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness.Therapeutic advances in respiratory diseaseReview
- Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a heterogeneous syndrome with numerous underlining molecular and inflammatory mechanisms contributing to the wide spectrum of clinical phenotypes. Multiple therapies targeting severe asthma with type 2 (T2) high inflammation are or soon will be available. T2 high inflammation is defined as inflammation associated with atopy or eosinophilia or an increase in cytokines associated with T-helper 2 lymphocytes. Omalizumab is a humanized anti-IgE monoclonal antibody and the first biologic therapy approved for moderate-severe allergic asthma. Despite the specificity of biologic therapies like omalizumab, clinical response is variable, with approximately 50% of treated patients achieving the primary outcome. A prior identification of the ideal candidate for therapy would improve patient outcomes and optimize the use of health care resources. As the number of biologic therapies for asthma increases, the goal is identification of biomarkers or clinical phenotypes likely to respond to a specific therapy. This review focuses on potential biomarkers and clinical history that may identify responders to omalizumab therapy for asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.